Overview

MK-3984 is a synthetic peptide analog of growth hormone-releasing factor (GRF, also known as GHRH) developed by Merck Research Laboratories as part of their exploration of modified GRF analogs for therapeutic stimulation of endogenous growth hormone (GH) secretion. The compound belongs to the broader class of GHRH agonists that act on the GHRH receptor (GHRH-R) expressed on pituitary somatotroph cells to trigger GH release in a pulsatile, physiological manner — an approach that preserves the natural feedback regulation of the GH/IGF-1 axis, unlike exogenous GH administration which suppresses endogenous production.

GRF analogs like MK-3984 were designed to overcome the limitations of native GHRH(1-44), which has a plasma half-life of only 5–7 minutes due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at the position 2 alanine residue. Structural modifications — including amino acid substitutions at key positions to resist enzymatic degradation, and truncation or extension of the peptide chain to optimize receptor binding — aim to produce compounds with improved pharmacokinetic profiles suitable for clinical use. This development approach parallels the better-known Modified GRF 1-29 (tesamorelin/CJC-1295 variants), which introduced substitutions at positions 2, 8, 15, and 27 of the GRF(1-29) fragment to achieve DPP-IV resistance and enhanced bioactivity. MK-3984 represents Merck's proprietary iteration within this competitive landscape of optimized GHRH analogs.

The therapeutic rationale for GHRH agonists centers on conditions of relative GH deficiency, including age-related somatopause, HIV-associated lipodystrophy, and growth disorders. By stimulating the body's own GH secretion rather than replacing it exogenously, GHRH analogs maintain pulsatile release patterns and physiological IGF-1 levels, potentially offering a safer long-term profile than recombinant GH. MK-3984 has been studied in clinical settings, though published data remain limited compared to more widely adopted analogs. In research contexts, it is categorized alongside other GHRH-based secretagogues such as CJC-1295, sermorelin, and tesamorelin, and is often used in combination with ghrelin mimetics like Ipamorelin or GHRP-6 for synergistic GH release.

Mechanism of Action

NPY5 Receptor Antagonism

MK-3984 is a potent, selective, non-peptide antagonist of the neuropeptide Y type 5 receptor (NPY5R), developed by Merck for the treatment of obesity. Neuropeptide Y (NPY) is one of the most potent orexigenic (appetite-stimulating) peptides in the central nervous system, and the Y5 receptor subtype plays a key role in mediating its effects on food intake and energy homeostasis in the hypothalamus.

Hypothalamic Appetite Circuitry

NPY is released from AgRP/NPY neurons in the arcuate nucleus of the hypothalamus in response to energy deficit signals (low leptin, high ghrelin). NPY acts on Y1 and Y5 receptors in the paraventricular nucleus (PVN) and lateral hypothalamus to stimulate feeding behavior, reduce energy expenditure, and promote fat storage. MK-3984 selectively blocks Y5R-mediated signaling, attenuating the orexigenic drive without affecting Y1, Y2, or Y4 receptor functions.

Downstream Metabolic Effects

By antagonizing NPY5R, MK-3984 reduces hypothalamic signals that promote hyperphagia and lipogenesis. In preclinical models, NPY5R antagonism decreased meal size, reduced preference for high-fat diet, and attenuated weight gain. The compound may also relieve NPY-mediated suppression of sympathetic outflow to brown adipose tissue, potentially enhancing thermogenesis and energy expenditure.

Clinical Development

MK-3984 advanced to Phase II clinical trials for obesity but demonstrated modest efficacy in weight reduction, consistent with the understanding that appetite regulation involves redundant and compensatory pathways (including Y1R, melanocortin, and GLP-1 systems). The compound exhibited good oral bioavailability and CNS penetration with an acceptable safety profile in human studies.

Reconstitution Calculator

Research

Safety Profile

As a growth hormone secretagogue, MK-3984 may cause side effects common to GH-elevating compounds including water retention, joint pain, and changes in insulin sensitivity. It is contraindicated in individuals with active malignancies due to the growth-promoting effects of elevated growth hormone. Long-term safety data is limited, and use should be under medical supervision.

Pharmacokinetic Profile